Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01255761 · ClinicalTrials.gov registry record · Phase 4
A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects
A Phase 4 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 736
- Enrollment target
NCT01255761: Completed Phase 4 study, sponsored by UCB Pharma.
NCT01255761 is a Phase 4 study that has completed, run by UCB Pharma. The registered enrollment target is 736 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (42% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01255761, a Phase 4 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 736 participants
- Enrollment target
Study Summary
Phase 4 study to evaluate a routine patient completed assessment (RAPID3) compared to a physician completed assessment (CDAI) to predict treatment success with subjects with moderate to severe rheumatoid arthritis
Primary Outcome
For subjects randomized to CDAI, response is defined as CDAI ≤10 or 20% improvement from Baseline. For subjects randomized to RAPID3, response is defined as RAPID3 ≤6 or 20% improvement from Baseline. CDAI is the sum of tender joint count, swollen joint count, Patient's Global Assessment of Disease Activity as assessed by Multi-dimensional Health Assessment Questionnaire (MDHAQ) subscore, and Investigator's Global Assessment of Disease Activity - VAS (VAS in cm). 28 joints are examined. RAPID3
Interventions
- BIOLOGICAL Certolizumab Pegol (CZP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 736 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
What the finished NCT01255761 record still lists
NCT01255761 is an interventional study that assigns participants to a tested intervention. The registered 736 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (42% higher).
The record links to 0 conditions, and to 1 intervention - of which Certolizumab Pegol (CZP) is the first listed.
NCT01255761 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01255761 about?
NCT01255761 is a clinical study titled "A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects". Phase 4 study to evaluate a routine patient completed assessment (RAPID3) compared to a physician completed assessment (CDAI) to predict treatment success with subjects with moderate to severe rheumatoid arthritis
What is the current status of trial NCT01255761?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 736 participants. The study started on 2010-11. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01255761?
The interventions under investigation include: Certolizumab Pegol (CZP) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01255761?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01255761's enrollment target sits among peer trials
736 112th of 2000 higher than 1,889 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05796141 · 736 participants · NA
Becoming United in Lifestyle Decisions
- NCT05947851 · 735 participants · Phase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- NCT05999084 · 735 participants
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
- NCT06825689 · 735 participants · NA
Unidos Contra el VPH
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia